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JNK and p38 phosphorylate a diverse set of sub-
strates and, consequently, can act in a context-
dependent manner to either promote or inhibit tumor
growth. Elucidating the functions of specific sub-
strates of JNK and p38 is therefore critical for our
understanding of these kinases in cancer. ATF2 is
a phosphorylation-dependent transcription factor
and substrate of both JNK and p38. Here, we show
ATF2 suppresses tumor formation in an orthotopic
model of liver cancer and cellular transformation
in vitro. Furthermore, we find that suppression of
tumorigenesis by JNK requires ATF2. We identify a
transcriptional program activated by JNK via ATF2
and provide examples of JNK- and ATF2-dependent
genes that block cellular transformation. Signifi-
cantly, we also show that ATF2-dependent gene
expression is frequently downregulated in human
cancers, indicating that amelioration of JNK-ATF2-
mediated suppression may be a common event dur-
ing tumor development.
INTRODUCTION
The stress-activated kinases JNK and p38 play an essential role
in the cellular response to a number of different extracellular and
intracellular signals including exposure to cytokines, growth fac-
tors, and various stresses. They regulate many key biological
processes, such as cellular proliferation and death, which func-
tion aberrantly in cancer. Accordingly, these kinases are pro-
posed to have critical roles in tumor development (Wagner and
Nebreda, 2009). However, the complexity of stress-dependent
signaling networks means that JNK and p38 have both pro-
and antitumorigenic functions. Consistent with a protumorigenic
role, these kinases are frequently found to be highly activated inCell Rehuman cancers and to support the proliferation of tumor-derived
cell lines (Esteva et al., 2004; Hui et al., 2008; Salh et al., 2002;
Yang et al., 2003). Conversely, comprehensive analysis of can-
cer genomes has revealed inactivating mutations in several
kinases lying upstream of JNK and p38, strongly implying a tu-
mor-suppressive role for these pathways. For example, a recent
survey of breast cancer genomes revealed mutations in MEKK1
in 6% of cancers, most of which resulted in protein truncation. In
this same study, LZK1 was also found to be mutated in some
breast cancers (Stephens et al., 2012). ASK1 and MLK1 have
been reported to be frequently mutated in melanomas (Stark
et al., 2012), leading to loss of their function, and the MAP2 ki-
nase MKK4, which directly activates JNK and p38, has been
identified as a ‘‘cancer gene’’ on the basis of its frequent muta-
tion in several cancers (Greenman et al., 2007).
The role of JNK and p38 in tumorigenesis has been studied in a
variety of mouse tumor models. p38 is inhibitory to oncogenic
Ras-mediated transformation in vitro (Dolado et al., 2007) as
well as liver and lung tumorigenesis in vivo (Hui et al., 2007; Ven-
tura et al., 2007). These studies support a tumor-suppressive
role for p38. The role of JNK is more complex, and depending
on the experimental setting, this kinase either promotes or an-
tagonizes tumorigenesis in mice. For example, studies using
JNK1/ mice indicate that JNK1 facilitates DEN-induced liver
tumor formation (Eferl et al., 2003; Hui et al., 2008; Sakurai
et al., 2006). However, JNK drives liver tumorigenesis by promot-
ing expression of hepatic cytokines in nonparenchymal liver
cells, and deletion of JNK specifically in hepatocytes reveals
its suppressive role in liver tumor development (Das et al.,
2011). Furthermore, although JNK supports tumor growth in
some tissues such as lung and gastric cancer (Cellurale et al.,
2011; Shibata et al., 2008), it exhibits potent tumor-suppressive
properties in mouse models of prostate and breast cancer (Cel-
lurale et al., 2010, 2012; Hu¨bner et al., 2012). Thus, a complex
picture emerges, in which JNK and p38 function in a context-
dependent manner to regulate tumorigenesis. In order to unravel
such complexity, a better understanding of the role of effector
substrates for the stress-activated protein kinases is required.ports 9, 1361–1374, November 20, 2014 ª2014 The Authors 1361
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Figure 1. Suppression of Ras-Mediated Transformation and Liver Tumorigenesis by ATF2
(A) Extracts from Atf2 WT (Atf2+/+, Atf7/, and p53/) and Atf2 KO (Atf2/, Atf7/, and p53/) hepatoblasts were immunoblotted for ATF2 and b-actin.
(B–D) Anchorage-independent growth of HRasV12-expressing Atf2WT and KOMEFs (B and C) and hepatoblasts (D). Values plotted are numbers of colonies per
dish; ± SD; n = 18 (three experiments 3 six dishes per experiment); *p < 0.05.
(legend continued on next page)
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JNK and p38 have many downstream targets including a
diverse set of transcription factors through which they can
initiate complex changes to gene expression. ATF2 is a sub-
strate of both JNK and p38 and belongs to the AP-1 family of
B-Zip-containing transcription factors. In response to diverse
stimuli, these kinases phosphorylate ATF2 at two key threonine
residues in the N-terminal transactivation domain (TAD), lead-
ing to its activation (Gupta et al., 1995). Several studies have
implicated ATF2 in cancer. High levels of phospho-ATF2 have
been detected in human melanoma samples, and a role for
ATF2 in driving progression of these tumors has been sug-
gested (Berger et al., 2003; Shah et al., 2010). Conversely,
ATF2 can inhibit tumor formation in some settings. After a la-
tency period of 60 weeks, ATF2 heterozygous mice develop
mammary tumors spontaneously, and furthermore, low levels
of ATF2 expression in human breast tumors have been re-
ported (Maekawa et al., 2007). ATF2 also inhibits tumor devel-
opment in a mouse model of skin cancer (Bhoumik et al., 2008),
and deletion of ATF2 in B cells leads to a resistance to
apoptosis and accelerates the onset of lymphoma in the
Em-Myc mouse model (Walczynski et al., 2014). Furthermore,
recent findings indicate that the SS18-SSX2 fusion protein
found in human synovial sarcomas derives its oncogenicity
from its ability to interact with ATF2 and to silence ATF2 target
promoters (Su et al., 2012).
In this study, we sought to clarify the role of ATF2, and its
requirement for JNK and p38 signaling, in cellular transformation
and tumorigenesis. By using an orthotopic model of liver cancer,
we demonstrate a tumor-suppression role for JNK, which is
effected via activation of ATF2-dependent transcription. Further-
more, we define an ATF2-dependent gene signature that is
decreased in several types of human cancer, consistent with a
tumor-suppressive role for JNK-ATF2 signaling.
RESULTS
ATF2 Suppresses Ras-Dependent Cellular
Transformation and Liver Tumorigenesis
To investigate the effect of ATF2 on oncogenic HRas-mediated
transformation, we utilized mouse embryonic fibroblasts
(MEFs), which allow for the conditional deletion of the ATF2
DNA-binding domain (Atf2Flox/Flox). ATF2 shares overlapping
functions with ATF7 during development (Breitwieser et al.,
2007). To eliminate the potential for redundancy, we deleted
ATF7 by crossing Atf2Flox/Flox mice with Atf7/ mice. To render
the cells susceptible to HRasV12-mediated transformation, we
deleted p53 by crossing Atf2Flox/Flox, Atf7/ mice with p53/
mice. Deletion of Atf2 was achieved in vitro by transient expres-
sion of Cre recombinase, using an adenoviral vector. This
approach led to complete deletion of the ATF2 DNA-binding(E–G) HRasV12-expressing Atf2 KOMEFs (F) or hepatoblasts (E and G) were tran
indicated; n = 18; ± SD; *p < 0.05.
(H) Bioluminescence imaging of mice injected with HRasV12- and luciferase-expr
cells/mouse; n = 6). Mice were imaged 14 days after cell injection.
(I) Bioluminescence of resected livers at day 14.
(J) Quantification of liver tumors. HRasV12- and luciferase-expressing Atf2WTand
cells/mouse; n = 12). *p < 0.05. Tumor nodules were enumerated 6 weeks after
Cell Redomain, generating cells with the genotype Atf2/, Atf7/ ,
p53/, referred to hereafter as Atf2 knockout (KO). Cells treated
with a control vector continue to express full-length ATF2 protein
and are referred to hereafter as Atf2 wild-type (WT) (Atf2+/+,
Atf7/ , p53/; Figure 1A).
To assess the role of ATF2 in cellular transformation, we
compared the growth of HRasV12-expressing Atf2 WT and
Atf2 KOMEFs in soft agar. Atf2 KO cells gave rise to significantly
greater numbers of colonies than did wild-type controls, indi-
cating that ATF2 suppresses cellular transformation (Figures
1B and 1C). Re-expression of ATF2 in Ras-transformed Atf2
KO MEFs impaired colony formation, confirming that the
observed phenotype was due to loss of ATF2 (Figures 1E and
1F). Notably, in the absence of HRasV12, Atf2 KO cells did not
form colonies in soft agar (Figure S1A), showing that loss of
ATF2 is not sufficient for transformation.
We next studied the role of ATF2 in tumor development in vivo
using an orthotopic mouse model of hepatocellular carcinoma,
which involves transformation of embryonic hepatoblasts
in vitro and their subsequent injection into preconditioned recip-
ient mice (Zender et al., 2006). Similarly to MEFs, Atf2 KO hepa-
toblasts displayed enhanced colony formation in soft agar (Fig-
ure 1D), which was efficiently rescued by re-expression of
ATF2 (Figure 1G). Although anchorage-independent growth of
Atf2 KO cells was enhanced, adherent growth was not signifi-
cantly affected (Figures S1B and S1C).
Next, HRasV12-transformed Atf2 KO and Atf2 WT hepato-
blasts were introduced into the spleen of recipient mice, from
where they home to the liver. Tumor growth was assessed
14 days later using luciferase-dependent luminescence. Prior
to injection, bioluminescence of Atf2 WT and KO cells was
similar (Figure S1D). However, a significantly higher level of
bioluminescence was observed in the mice injected with
HRasV12-transformed Atf2 KO cells, indicating greater tumor
growth (Figure 1H). Analysis of dissected livers confirmed the
presence of large tumor masses in all (6/6) mice injected with
Atf2 KO cells. In comparison, in theAtf2WT group, tumor growth
was reduced and detected in only four of the six recipient mice
(Figure 1I). Both Atf2 WT and KO cells formed trabecular, pseu-
doglandular, and solid histological tumor types typical of human
hepatocellular carcinoma (HCC) (not shown).
To enumerate tumors, the experiment was repeated with
fewer hepatoblasts being injected, and livers were assessed af-
ter 6 weeks. Multiple small tumor nodules were observed in 92%
(11/12) of recipient mice injected with Atf2 KO cells and 75% (9/
12) of recipient mice injected with Atf2 WT cells. However, Atf2
KO cells generated approximately 3-fold more tumor nodules
(Figure 1J). Thus, both the number and size of tumors was
greater in the absence of ATF2, indicating that ATF2 suppresses
HRasV12-driven liver tumorigenesis.sduced with recombinant adenoviruses (Ad-) expressing either ATF2 or GFP as
essing Atf2WT (upper panel) and Atf2 KO (lower panel) hepatoblasts (1.53 106
Atf2KO hepatoblasts were injected into the spleen of recipientmice (0.23 106
cell transplantation.
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Figure 2. p38 MAPK Is Not Required for
ATF2-Mediated Suppression of Ras Trans-
formation
(A) HRasV12-expressing Atf2 KO hepatoblasts
were transduced with Ad-ATF2, Ad-ATF2-AA, Ad-
C2/ATF2, or Ad-GFP, and colony formation in soft
agar was assessed. ± SD; n = 18; *p < 0.05.
(B and C) HRasV12-expressing Atf2 WT and KO
MEFs (B) or hepatoblasts (C) were transducedwith
Ad-MKK6EE or Ad-GFP, and anchorage-inde-
pendent growth was analyzed. ± SD; n = 18; *p <
0.05.
(D) Anchorage-independent growth of HRasV12-
expressing p38WT and KOMEFs transduced with
Ad-ATF2, Ad-C2/ATF2, Ad-ATF2AA, and Ad-GFP.
± SD; n = 18; *p < 0.05.
(E) p38a WT and KO cells transduced with either
Babe-HRasV12 or Babe-Empty control retrovirus
were treated with Ad-GFP, Ad-ATF2, and Ad-C2A.
FACS analysis, employing a redox-sensitive fluo-
rophore, dihydroethidium (DHE), was used to
detect cellular ROS. ROS levels were calculated as
(BABE-RAS mean DHE fluorescence/BABE mean
DHE fluorescence) 3 100. ± SD; n = 3; *p < 0.05.Phosphorylation of the ATF2 TAD Is Required for
Suppression of HRasV12-Dependent Transformation
To examine the role of the ATF2 TAD in suppression of onco-
genic Ras-mediated transformation, we generated an adenoviral
vector expressing amutant ATF2, wherein two keymitogen-acti-
vated protein (MAP) kinase phosphorylation sites are changed to
alanine (ATF2AA). This mutant is transcriptionally inactive (Fig-
ures S2A and S2B). Unlike wild-type ATF2, ATF2AA was unable
to efficiently suppress colony formation in soft agar, indicating
that phosphorylation of the TAD is important for suppression of
HRasV12-dependent transformation by ATF2 (Figure 2A). In
addition, we constructed an adenoviral vector expressing a
constitutively active form of ATF2 (C2/ATF2; Steinmu¨ller and
Thiel, 2003), which does not require stress-dependent phos-
phorylation for its activity (Figures S2C and S2D). When ex-
pressed in Ras-transformed Atf2 KO cells, C2/ATF2 markedly
suppressed anchorage-independent growth (Figure 2A). These
lines of evidence demonstrate that ATF2-dependent suppres-
sion of cellular transformation is dependent upon transcriptional
activation.
ATF2-Mediated Suppression of Ras-Mediated
Transformation Is Independent of p38 MAP Kinase
Both JNK and p38 efficiently phosphorylate ATF2 and can
suppress cellular transformation and tumor development. To
address the potential role of p38, we utilized an activated mutant
ofMap2k6 (MKK6EE), which activates p38 specifically. MKK6EE
efficiently suppressed colony formation in both Atf2WT and Atf21364 Cell Reports 9, 1361–1374, November 20, 2014 ª2014 The AuthorsKO MEFs (Figure 2B) and hepatoblasts
(Figure 2C), showing that, in this setting,
p38 does not require ATF2 to mediate
its suppressive activity. p38a knockout
MEFs form greater numbers of colonies
in soft agar than p38 WT MEFs whentransformed by oncogenic Ras (Dolado et al., 2007). ATF2
strongly impaired this enhanced colony formation of p38a KO
cells (Figure 2D), showing that ATF2 does not require p38a-me-
diated phosphorylation for the suppression of transformation.
Notably, suppression by ATF2-AA was impaired (Figures 2D
and S2E), confirming that phosphorylation of ATF2 is required
for suppression of transformation and, further, that this phos-
phorylation must still occur in p38a knockout cells. Given that
p38a has been shown to suppress Ras transformation by
lowering intracellular reactive oxygen species (ROS) levels (Do-
lado et al., 2007), we asked whether ATF2 also suppresses col-
ony formation by controlling ROS. As expected, p38a knockout
cells generated high levels of ROS in response to HRasV12
transformation (Figure 2E), but ATF2 expression had no influence
on these elevated ROS levels (Figure 2E). Thus, ATF2 and p38
can suppress transformation independently of each other and
by distinct mechanisms.
JNK Is Required for ATF2 Function
In response to a range of stresses, ATF2 was efficiently phos-
phorylated in p38a knockout cells (Figure S3A) but was sensitive
to specific JNK inhibition (Figure S3B). To further confirm this
finding, ATF2 phosphorylation was examined in Jnk1/2 WT
(Jnk1/2+/+, p53/) and Jnk1/2 KO (Jnk1/2/, p53/) MEFs.
Loss of JNK led to a severe impairment of ATF2 phosphorylation
despite the fact that p38 was strongly activated in response to
stress (Figure S3C). Furthermore, binding of ATF2 to the c-Jun
promoter, a known target gene, was impaired in Jnk1/2 KO cells
(Figure S3D). Thus, JNK is indispensable for ATF2 function,
strongly indicating that suppression of tumorigenesis by ATF2
is likely to be JNK dependent.
JNK1 Suppresses Oncogenic Ras-Mediated
Transformation via ATF2
Because ATF2 inhibited formation of liver tumors and requires
JNK for activation, we asked whether ATF2 is required for tumor
suppression by the JNK pathway. Expression of constitutively
active JNK (JNK1-CA; Lei et al., 2002) significantly elevated
the level of ATF2 phosphorylation in Ras-transformed NIH 3T3
cells (Figure S3E) compared to GFP and kinase-dead JNK con-
trols. Phosphorylation of c-Jun by JNK-CA was also observed
(Figure S3E). Expression of JNK1-CA in HRasV12-transformed
NIH 3T3 cells significantly suppressed colony formation whereas
JNK1-KD or GFP had no effect (Figure 3A). Thus, although
genetic ablation of JNK renders cells resistant to Ras transfor-
mation (Cellurale et al., 2011), increased JNK activity causes
phosphorylation of its downstream substrates and impairs
Ras-dependent transformation.
Next, we asked whether JNK1-CA suppresses transformation
and tumorigenesis via ATF2. JNK1-CA strongly suppressed col-
ony formation in Atf2 WT cells whereas only minor suppression
was observed in the Atf2 KO cells (Figures 3B and 3C). Expres-
sion of JNK1-KD had no effect on colony formation in soft agar
(Figures 3B and 3C). Equal expression of JNK-CA in Atf2 WT
and Atf2 KO cells was confirmed by western blot analysis (Fig-
ure S3F). Furthermore, re-expression of ATF2 in Atf2 KO cells
restored JNK1-CA-mediated suppression of transformation
(Figure 3D). Consistent with these findings, we observed a
marked suppression of liver tumorigenesis by JNK1-CA when
expressed in Atf2 WT, but not Atf2 KO cells (Figure S3G).
Furthermore, re-expression of ATF2 in Atf2 KO cells together
with JNK1-CA resulted in strong suppression of liver tumorigen-
esis, whereas coexpression of JNK1-CA and GFP resulted only
in a modest reduction (Figures 3E and S3H). These results indi-
cate that JNK activity suppresses liver tumorigenesis in vivo
and requires ATF2.
The Cellular Response to ATF2 Activation and
Identification of ATF2-Dependent Transcriptional
Targets
To identify ATF2 transcriptional targets involved in cellular trans-
formation, we carried out gene-expression profiling, employing
constitutively active ATF2 (C2/ATF2), which allows for the
expression of ATF2 targets in the absence of stress (Figures
S2C and S2D).
First, we assessed the biological consequences of ATF2-
dependent gene expression. Expression of C2/ATF2 in hepato-
blasts led to a striking loss of cellular proliferation within 16 hr
(Figures 4A and 4B), and within 48 hr, we observed the onset
of cell death detected by annexin V staining (Figures 4C and
4D). Note that expression of WT ATF2 did not affect cell viability
(Figure 4D), consistent with our observation that overexpression
of ATF2 does not induce target gene expression unless accom-
panied by stress (Figures S2A and S2B). Treatment of C2/ATF2-
transduced cells with cycloheximide (Figures 4E and 4F) or
actinomycin D (data not shown) significantly blocked the induc-Cell Retion of apoptosis, suggesting that target gene expression is
required for the induction of cell death by active ATF2.
To identify ATF2 target genes, we expressed C2/ATF2 or GFP
in hepatoblasts for 8 hr and performed microarray analysis. Em-
ploying a threshold of a 3-fold or greater change in expression,
we observed 270 differentially expressed genes (244 up- and 26
downregulated; p < 0.01) including previously reported ATF2
targets, e.g., ATF3, DUSP10, and JUN. Next, we confirmed
that the microarray strategy successfully identified authentic
targets of wild-type ATF2. We selected a subset of genes, all
of which were induced by 4-fold or greater in the microarray
experiment, and confirmed that the majority of these selected
genes were dependent on ATF2 for their expression by
comparing their transcript levels in Atf2 WT versus Atf2 KO
cells, in the presence or absence of methyl methanesulfonate
(MMS) stress, using quantitative RT-PCR (qRT-PCR) (Table
S1). Because JNK activity is critical for ATF2 activation (Fig-
ure S3C), we compared the expression of ATF2-dependent
genes in Jnk1/2 WT versus Jnk1/2 KO MEFs and found that
the majority of these were expressed in a JNK-dependent
manner (Table S2). Furthermore, analysis of chromatin immuno-
precipitation sequencing (ChIP-seq) data in the ENCODE
database (Thomas et al., 2007) confirmed the presence of
ATF2-binding sites in 219 out of 270 genes from the microarray
gene set (Table S3), suggesting that the majority of genes we
identified are direct targets of ATF2.
As presented in Figure 3, expression of active JNK led to inhi-
bition of tumorigenesis in an ATF2-dependent manner. To
assess ATF2 target gene expression under these conditions,
we expressed JNK1-CA together with ATF2, ATF2-AA, or GFP
in Atf2 KO cells and measured the expression of genes selected
from the microarray data by qRT-PCR. JNK1-CA displayed
limited or no ability to induce expression of the microarray tar-
gets when expressed in Atf2 KO cells. On the other hand, coex-
pression of JNK1-CA with ATF2 led to a significant induction of
several of the identified targets (Table S4). This induction
depended entirely on the phosphorylation of ATF2, because co-
expression of JNK1-CA and ATF2-AA did not lead to transactiva-
tion of the targets. Thus, we identified a set of genes whose
expression is induced by JNK via phosphorylation of ATF2.
Inhibition of Cellular Transformation by Selected
JNK-ATF2-Dependent Target Genes
Next, we wished to ascertain whether any of the identified genes
were capable of suppressing cellular transformation mediated
by oncogenic Ras. We selected six candidate genes for further
analysis. Each of the genes was confirmed to be a transcriptional
target of JNK signaling via ATF2. Thus, their expression is
impaired in Atf2 KO cells versus WT controls (Figure 5A) and in
JNK1/2 KOMEFs versusWT controls (Figure 5B; note, however,
that NTS expression was not reduced in JNK1/2 KO cells). In
addition, expression of each of these genes was induced by
JNK1-CA via phosphorylation of ATF2 (Figure 5C). HRasV12-
transformed Atf2WT and KOMEFs were infected either with ad-
enoviruses expressing each of the JNK-ATF2-dependent targets
or a GFP-expressing control. Subsequently, the efficiency of
cellular transformation was monitored by assessing colony
formation in soft agar. Expression of three of the candidatesports 9, 1361–1374, November 20, 2014 ª2014 The Authors 1365
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(PPP2R5B,GABRA1, andRCAN1) suppressed colony formation
(Figure 6A). Although some suppression of colony formation was
observed in Atf2 WT MEFs, the suppression was most clearly
observed in Atf2 KO MEFs, where exogenous expression of
each of these genes substantially suppressed the Atf2 KO
phenotype. As shown in Figure 6B, expression of GABRA1
induced apoptosis in both Atf2 WT and KO cultures, which
may account for its ability to impair anchorage-independent
growth. On the other hand, expression of neither PPP2R5B nor
RCAN1 induced significant amounts of apoptosis, indicating
that these genes likely inhibit transformation by another
mechanism. Therefore, we measured the effect of expressing
PPP2R5B and RCAN1 on cell-cycle progression and found
that both genes led to a reduction of cells in S phase (Figures
6C and 6D). Interestingly, whereas PPP2R5B expression
increased the number of cells in G1/G0, Rcan1 caused cells to
accumulate in G2. These data identify transcriptional targets of
ATF2 that are either proapoptotic or antiproliferative and capable
of inhibiting HRasV12-mediated cellular transformation.
JNK- and ATF2-Dependent Transcripts Are
Underexpressed in Human Tumors
To determine whether our findings are relevant to human tumor
development, we examined the expression of ATF2-dependent
transcriptional targets in human tumors through interrogation
of tumor-derived transcriptomic data available in the public
domain.
First, we examined expression of ATF2 targets in human HCC.
We observed that RCAN1 expression was markedly downregu-
lated in HCCswhen compared to normal tissue in three indepen-
dent studies, consistent with a tumor-suppressive role of ATF2 in
HCC (Figure 7A). In addition, we noted that PPP2R5B and
GABRA1were also underexpressed in HCC samples (Figure S4).
To obtain a more-comprehensive picture of the behavior of
ATF2-dependent transcripts in tumors, we used our microarray
data to compile an ATF2 gene signature comprising 31 genes.
Each gene in the signature was shown to be induced by JNK-
mediated phosphorylation of ATF2 as shown in Table S4. Next,
we analyzed the Oncomine data set, comparing expression of
the ATF2 gene signature in normal tissue versus tumor samples,
expanding the analysis to encompass all tumor types. We
observed a significant (p < 0.001) overlap between the ATF2
gene signature and the top-ranking (1%–10%) underexpressed
genes in 8/20 cancer types, including brain, breast, colorectal,
and lung (Table S5). Notably, in no case was the ATF2 gene
set significantly overexpressed. The downregulation of ATF2 tar-
gets was particularly striking in breast cancers. As an example,
the heatmap presented in Figure 7B illustrates the reduced
expression of the ATF2 gene signature in mucinous breast carci-Figure 3. JNK Suppresses HRasV12-Dependent Transformation and T
(A) Anchorage-independent growth of HRasV12-transformed NIH 3T3 cells expr
(B) Anchorage-independent growth of HRasV12-transformed Atf2 WT and KO he
*p < 0.05.
(C) As in (B), except Atf2 WT and KO MEFs were used. ± SD; n = 18; *p < 0.05.
(D) Anchorage-independent growth of HRasV12-transformed Atf2 KO hepatoblas
*p < 0.05.
(E) Liver tumor formation in mice injected with HRasV12-transformed Atf2 KO he
Cell Renomas analyzed by Curtis et al. (2012). For this data set, 13 of the
31 genes comprising the ATF2 gene signature fell within the top
10% of underexpressed genes in tumor versus normal samples.
In addition, we identified several ATF2 targets (including RCAN1)
that are consistently downregulated in ductal and lobular tu-
mors, as well as the rarer medullary, tubular, and mucinous
breast cancer types (Figure 7C). Furthermore, ATF2 targets
were underexpressed in ductal carcinoma in situ samples, indi-
cating that loss of their expression may be an early event in
development of breast tumors. The underexpression of ATF2
targets was also evident in breast cancer data from The Cancer
Genome Atlas study (Figure 7D). Thus, loss of ATF2-dependent
transcription appears to be a common feature of breast cancer.
These findings, when taken alongside our findings in the mouse
model, indicate a role for ATF2-dependent transcription in tumor
suppression.
DISCUSSION
ATF2 functions in a context-dependent manner to either pro-
mote or antagonize tumorigenesis. In this study, we show that
ATF2 inhibits anchorage-independent growth of cells trans-
formed by oncogenic Ras and suppresses tumor formation in a
mouse model of liver cancer. This suppression requires phos-
phorylation of its transactivation domain by JNK. We identify a
JNK-ATF2-dependent gene signature that is downregulated in
many human tumors, strongly supporting a role for JNK and
ATF2 in the inhibition of cancer development in humans. Our
observation that JNK suppresses the development of liver tu-
mors is consistent with the results of Das et al. (2011), who
demonstrated that hepatocyte-specific deletion of JNK pro-
motes liver tumor formation. Although other groups have shown
that JNK can promote liver tumorigenesis (Hui et al., 2008; Sa-
kurai et al., 2006), this effect involves JNK-dependent expres-
sion of cytokines in liver stromal cells (Das et al., 2011). Given
that ATF2 is an effector of JNK-dependent gene expression, it
is possible that ATF2 also influences tumor development by di-
recting transcription in stromal cells. Further studies are needed
to address this question. Hyperactivation of Ras signaling, due
either to increased expression of HRas or silencing of negative
regulatory proteins (Calvisi et al., 2011; Newell et al., 2009), is a
common feature of HCC. Its importance in tumor development
is underscored by the favorable responses seen in some patients
treated with the Raf kinase inhibitor sorafenib (Galmiche et al.,
2014). In addition, activating mutations in HRas are frequently
detected in mouse liver tumors induced by chemical carcino-
gens (Jaworski et al., 2005).These observations support the rele-
vance of the Ras-driven HCC model we have used in these
studies of ATF2. However, it will be of interest to determineumorigenesis via ATF2
essing GFP, JNK1-CA, or JNK-KD as indicated. ± SD; n = 18; *p < 0.05.
patoblasts expressing GFP, JNK1-CA, or JNK-KD as indicated. ± SD; n = 18;
ts expressing GFP, ATF2, JNK1-CA, and JNK1-KD as indicated. ± SD; n = 18;
patoblasts expressing GFP, ATF2, and JNK1-CA as indicated; n = 5.
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Figure 4. Active ATF2 Blocks Cellular Proliferation and Causes Apoptosis
(A) Atf2WT hepatoblasts were transduced with adenoviruses expressing either GFP or C2/ATF2 and harvested for cell-cycle analysis by FACS 16 hr later. Typical
results are shown.
(B) Quantification of (A). ± SD; n = 3; *p < 0.05.
(C) Atf2WT hepatoblasts expressing either GFP or C2/ATF2 were harvested 48 hr after viral transduction, and apoptosis was assessed by FACS. Typical results
are shown.
(D) Quantification of (C). ± SD; n = 3; *p < 0.05.
(E) Atf2 WT hepatoblasts were transduced with adenoviruses expressing either GFP or C2/ATF2, treated with cycloheximide (CHX) or vehicle control, and
harvested for FACS analysis 48 hr later.
(F) Quantification of (E). ± SD; n = 3; *p < 0.05.whether ATF2 can also suppress tumor formation driven by other
oncogenes implicated in HCC such as beta-catenin.
We selected six ATF2-dependent target genes identified
by microarray and tested their ability to impair RasV12-depen-
dent transformation. Exogenous expression of three genes,
PPP2R5B, GABRA1, and RCAN1, blocked anchorage-indepen-
dent growth of Ras-transformed MEFs, effectively reversing
the enhanced colony formation observed in ATF2 KO cells.
PPP2R5B encodes a PP2A-regulatory subunit belonging to the1368 Cell Reports 9, 1361–1374, November 20, 2014 ª2014 The AutB56 family of proteins (Arnold and Sears, 2008). We show that
its overexpression impaired proliferation of MEFs transformed
by oncogenic Ras and caused an accumulation of cells in G1.
Two substrates have been identified for the B56b-containing
PP2A holoenzyme: it regulates Akt phosphorylation in the
context of insulin signaling (Rodgers et al., 2011) and interacts
with the proto-oncogene, Pim-1, mediating its dephosphoryla-
tion and subsequent degradation (Ma et al., 2007). Both Akt
and Pim-1 are pro-oncogenic kinases, and it will be of interesthors
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to determine whether JNK and ATF2 can regulate their function
via B56b expression. GABRA1 encodes the alpha 1 subunit of
the GABA receptor. Methylation of theGABRA1 promoter region
has been detected in a cohort of colorectal tumors, with an
accompanying drop in expression (Lee et al., 2012). In addition,
loss of GABRA function in brain tumors is frequently seen and
loss of expression is particularly striking in glioblastoma (Labra-
kakis et al., 1998). This would be consistent with a suppressive
role for GABRA1 in the development of such tumors. RCAN1
(also known as DSCR1—Down syndrome critical region 1) en-
codes a regulator of the calcium-dependent phosphatase calci-
neurin, which in turn activates the NFAT family of transcription
factors. RCAN1 is a candidate tumor suppressor that can
impede angiogenesis by inhibiting the proliferation of endothelial
cells (Baek et al., 2009). We found that exogenous expression of
RCAN1 inhibited proliferation of Ras-transformed MEFs, which
may explain its ability to inhibit anchorage-independent growth
of these cells. Analysis of Oncomine data sets revealed that
RCAN1 is significantly underexpressed in HCCs and a range of
other tumor types, implying that increased calcineurin-NFAT
signaling may occur in many tumors. Indeed, aberrant NFAT
function has been implicated in the proliferation and survival of
several tumor types including liver cancer (Mu¨ller and Rao,
2010; Wang et al., 2012). Interestingly, the calcineurin-NFAT-
and JNK-signaling pathways are known to be coordinately regu-
lated: calcineurin interacts with, and activates, ASK-1, leading to
activation of JNK. On the other hand, phosphorylation of NFAT
proteins by JNK inhibits their translocation to the nucleus
(Chow et al., 1997). Therefore, the activation ofRCAN1 transcrip-
tion by ATF2may represent another layer of control exercised by
JNK over NFAT function. To date, we have characterized the
response of Ras-transformed cells to just six of the genes iden-
tified in the microarray data, and we anticipate that several other
ATF2-dependent genes contribute to the antioncogenic effects
described in this study. Indeed, we cannot rule out the possibility
that ATF2 promotes expression of other JNK substrates that
participate in tumor suppression. Furthermore, it should be
noted that JNK may regulate ATF2 function by phosphorylating
other factors present in the ATF2-transcription complex.
The analysis of various gene-expression tumor data sets high-
lights a strong tendency for ATF2 targets to be underexpressed
in hepatocellular carcinoma and several other tumor types.
Intriguingly, there is widespread underexpression of JNK-ATF2
transcriptional targets in breast tumors. Notably, loss of ATF2
function is sufficient to promote breast tumor formation: Mae-
kawa et al. (2007, 2008) report the spontaneous development
of mammary tumors in ATF2 heterozygous mice, which they
attribute to impaired expression of maspin and GADD45a in
ATF2 heterozygous (and knockout) MEFs and tumors. Further-
more, histological analysis of human breast tumors by Knippen
et al. (2009) demonstrated that high expression of phosphory-
lated (and therefore transcriptionally active) ATF2 correlatedFigure 5. Identification of Genes Expressed in an ATF2- and JNK-Depe
(A) Gene expression was assessed by qPCR of RNA from Atf2WT and KO hepato
(B) As in (A), except JNK1/2 WT and JNK1/2 KO MEFs were compared; ± SD; n
(C) Gene expression was assessed by qPCR of RNA from Atf2 KO hepatoblasts tr
the indicated combinations; ± SD; n = 3; *p < 0.05.
1370 Cell Reports 9, 1361–1374, November 20, 2014 ª2014 The Autwith prolonged survival. These findings are consistent with a tu-
mor-suppressive role for ATF2 in breast. Our findings raise the
possibility that several ATF2-dependent target genes may be
involved in actively suppressing breast tumor formation.
At this stage, we do not know how downregulation of ATF2-
dependent gene expression in tumors occurs. One possibility
is that somatic mutations in JNK, or its upstream kinases, leads
to impaired ATF2 activation. As yet, however, the impact of can-
cer-associated mutations in stress-signaling kinases on ATF2
function remains to be examined. Another possibility is that
epigenetic silencing of ATF2 targets occurs during tumor devel-
opment. The SS18-SSX fusion protein provides a specific
example of oncogenesis, involving epigenetic regulation of
ATF2 targets. In synovial sarcomas, SS18-SSX forms a protein
complex with TLE1 and DNA-associated ATF2. This targets the
epigenetic corepressor function of TLE1 to ATF2 target pro-
moters and silences transcription—an effect that is required for
the oncogenic function of the fusion protein (Su et al., 2012). In
principle, therefore, epigenetic inhibition of ATF2 transcription
could promote tumor development in other settings, and there
is widespread evidence that enzymes involved in epigenetic
modification of chromatin often function aberrantly in tumor
cells, leading to alterations in transcriptional programs.
In summary, our data indicate that JNK and ATF2 cooperate to
drive a transcriptional program that can suppress tumor devel-
opment. Further studies are ongoing to define in detail the nature
of this program.
EXPERIMENTAL PROCEDURES
Reagents
The following cell lines were employed: NIH 3T3 (American Type Culture
Collection; LGC Standards UK); Jnk1/2+/+, p53/ and Jnk1/2/,p53/
MEFs (a kind gift of Prof. R.J. Davis); and p38+/+, p38/ MEFs (a kind gift of
Prof. A. Nebreda). Cultivation of hepatoblasts and MEFs is described in the
Supplemental Experimental Procedures. MKK6EE (Raingeaud et al., 1996)
and MKK7-JNK1 (Lei et al., 2002) coding sequences were obtained from
Addgene.
Cre-Mediated Deletion of ATF2 Sequences
Ad-GFP and Ad-CRE-GFP virus stocks were obtained from Gene Transfer
Vector Core (University of Iowa). Cells were incubated with 0.5–1 ml of
virus in serum-free Dulbecco’s modified Eagle’s medium (DMEM) for
30–60 min at 37C. Cells were sorted for GFP expression 24–48 hr post-
infection by fluorescence-activated cell sorting (FACS) and expanded in
culture.
Mice, Chimeric Mouse Model for Hepatocellular Carcinoma
In vivo experiments were approved by the Cancer Research UK (CRUK) Man-
chester Institute Animal Ethics Committee and performed under a project li-
cense issued by the United Kingdom Home Office, in keeping with the Animal
Scientific Procedures Act 1986. C57BL/6 mice were purchased from Harlan.
ATF2f/f and ATF7/ mice are described in a previous report (Breitwieser
et al., 2007). The chimeric mouse model for hepatocellular carcinoma is
described in (Zender et al., 2006) and in Supplemental Experimentalndent Manner
blasts treated with 1 mMMMS or vehicle control for 3 hr; ± SD; n = 3; *p < 0.05.
= 3; *p < 0.05.
ansduced with adenoviruses expressing GFP, ATF2, ATF2AA, and JNK1-CA in
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Figure 6. Inhibition of Cellular Transforma-
tion by Selected JNK-ATF2-Dependent
Targets Genes
(A) Anchorage-independent growth of HRasV12-
transformed Atf2 WT and KO MEFs expressing
the indicated ATF2-dependent target genes. ± SD;
n = 18; *p < 0.05.
(B) Atf2 WT and KO MEFs were transduced with
adenoviruses expressing the indicated ATF2-
dependent target genes, and apoptosis was as-
sessed by FACS 48 hr later. ± SD; n = 3; *p < 0.05.
(C) Atf2 WT and KO MEFs were transduced with
adenoviruses expressing the indicated ATF2-
dependent target genes and harvested for cell
cycle analysis by FACS. The FACS plots show
typical results obtained when either PPP2R5B or
RCAN1 is expressed in Atf2 KO MEFs.
(D) Quantification of (C). ± SD; n = 3; *p < 0.05.Procedures. Imaging of tumors in vivo is described in Supplemental Experi-
mental Procedures.
Cell Growth and Colony Formation in Soft Agar
To assess their adherent growth rate, cells were plated at 8,000/well on 24-well
plates and cultured for 5 days. Cell density wasmeasured daily by staining with
0.1% crystal violet. Crystal violet was subsequently dissolved in 2% SDS, and
absorbance at l = 595 nm was measured. To assess growth in soft agar, cells
were seeded in a semisolid medium comprising 0.35% agarose in DMEM andCell Reports 9, 1361–1374, No10% fetal bovine serum (FBS) (5,000/well of a 6-
well plate). One milliliter of this suspension was
overlaid onto a base layer of 0.5% agarose in
DMEM 10% FBS. The plates were incubated for
14 days and stained with iodonitrotetrazolium
chloride (0.5 mg/ml) overnight. Colonies were
counted by processing scanned images using
ImageJ software.
ROS Measurement
To assess intracellular ROS levels, p38+/+ and
p38/ MEFs were stained with dihydroethidium
(DHE) (10 mg/ml) for 30 min and trypsinized, and
the mean fluorescence was measured by FACS.
Kinase Inhibitors
JNK inhibitors SP600125 (Tocris Bioscience;
1496), BI-87G3 (Calbiochem; 420142), and MEK
inhibitor PD98058 (Tocris Bioscience; 1213) were
used at a final concentration of 10 mM. DMSO
(Sigma; D2650) was used as a vehicle control for
each inhibitor.
Cell Cycle and Apoptosis Assays
Cells were labeled with bromodeoxyuridine (BrdU)
for 15min and fixed in 70% ethanol. Histones were
extracted in 0.1M HCl and 0.5% Triton X-100 for
10 min on ice. After resuspension in water, cells
were heated to 95C for 10 min and then cooled
on ice. PBS/0.5% Triton was used for permeabili-
zation. To stain, cells were incubated with anti-
BrdU (Roche; 11170376001) diluted in PBS/0.1%
BSA. Detection was via a fluorescent goat anti-
mouse secondary antibody (Life Technologies;
A21236). Apoptosis was measured by FACS anal-
ysis of Annexin V (Biolegend; 640912) and phos-phatidylinositol-stained cells (25 mg/ml; Sigma; P4864). For cycloheximide
treatment, Ad-C2/ATF2-infected cells were treated with 3 mM of cyclohexa-
mide (Sigma; C4859) and apoptosis was measured 48 hr later.
qPCR and ChIP
RNA was extracted using a GenElute Total RNA extraction kit (Sigma;
RTN350). cDNA synthesis was performed using aQuantitect reverse transcrip-
tion kit (QIAGEN; 205313). Quantitative PCR was performed using Jumpstart
qPCR ready mix for probes (Sigma D6442) and the Universal Probe Libraryvember 20, 2014 ª2014 The Authors 1371
Rank P-value Fold Change Gene
29 2.83E-40 -2.53 CREB5
178 6.20E-30 -2.58 SLC25A25
361 6.69E-25 -5.07 PAMR1
533 4.45E-22 -5.02 RCAN1
943 1.23E-17 -5.66 ATF3
976 2.32E-17 -7.79 KRT17
1110 3.55E-16 -1.60 DENND5B
1258 4.67E-15 -4.39 EGR2
1326 1.40E-14 -2.87 PDLIM3
1337 1.62E-14 -1.76 NR4A3
1479 2.12E-13 -1.36 MCAM
1528 4.43E-13 -1.70 DAAM1
1545 5.77E-13 -1.28 PPP2R5B
2200 1.18E-9 -1.33 ANGPTL1
3009 7.26E-7 -1.21 ATP6V0A4
3367 5.47E-6 -1.09 CALCA
4020 9.81E-5 -1.46 BTG2
4650 7.12E-4 -1.47 TNFAIP6
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7490 0.085 -1.02 NTS
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1.40E-63 CREB5
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4.01E-23 PPP2R5B
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2.03E-4 CALCA
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1 - Breast Phyllodes tumour vs normal
2 - Ductal Breast Carcinoma In Situ vs normal
3 - Invasive Breast Carcinoma vs normal
4 - Invasive Ductal Breast Carcinoma vs normal
5 - Invasive Ductal and Invasive Lobular Breast Carcinoma vs normal
6 - Invasive Lobular Breast Carcinoma vs normal
7 - Medullary Breast Carcinoma vs normal
8 - Mucinous Breast Carcinoma vs normal
9 - Tubular Breast Carcinoma vs normal
p-Value Gene
7.65E-19 CREB5
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1 2 3 4 5 6 7 8 9 10
1 - Curtis et al. Invasive breast carcinoma vs normal
2 - Curtis et al. Invasive ductal and invasive lobular carcinoma vs normal
3 - Curtis et al. Invasive ductal carcinoma vs normal
4 - Curtis et al. Invasive lobular carcinoma vs normal
5 - Curtis et al. Mucinous breast carcinoma vs normal
6 - TGCA Invasive breast carcinoma vs normal
7 - TGCA Invasive ductal and invasive lobular carcinoma vs normal
8 - TGCA Invasive ductal carcinoma vs normal
9 - TGCA Invasive lobular carcinoma vs normal
10 - TGCA Mucinous breast carcinoma vs normal
C D
normal tumour normal tumour normal tumour
(legend on next page)
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system (Roche). TBP and TAF6 housekeeper genes were used for normaliza-
tion of data. ChIP was performed using an ATF2-specific antibody (E243; Milli-
pore; 04-1021) and Simple ChIP reagents (Cell Signaling Technology no.
9002), according to manufacturer’s instructions. qPCR and ChIP primer se-
quences are presented in Table S6.
Oncomine
Oncomine was used for analysis and visualization of JNK- and ATF2-depen-
dent transcripts in normal and tumor samples (https://www.oncomine.org/
resource/login.html; Thermo Fisher Scientific).
ACCESSION NUMBERS
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GSE50530. Details are in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2014.10.043.
AUTHOR CONTRIBUTIONS
M.G. and S.L. designed and carried out experiments and prepared the manu-
script. S.K. carried out experiments and assisted in manuscript preparation.
J.T. and Y.L. carried out analysis of microarray and ChIP-seq data. J.W. assis-
ted in experimental work. G.T. designed and characterized C2/ATF2. W.B. de-
signed ATF2 knockout strategy and mouse breeding. N.J. designed the study,
supervised the team, and prepared the manuscript.
ACKNOWLEDGMENTS
We would like to thank Professor Roger Davis, Professor Angel Nebreda, Pro-
fessor Scott Lowe, and Dr. David Gilham for kindly providing reagents. We
thank the staff of the CRUK Manchester Institute Biological Resource Unit,
Molecular Biology Core Facility, and FACS department for their excellent sup-
port. We are grateful to Dr. John Brognard for his critical reading of the manu-
script. This work was funded by Cancer Research UK.
Received: September 3, 2013
Revised: July 16, 2014
Accepted: October 14, 2014
Published: November 13, 2014
REFERENCES
Arnold, H.K., and Sears, R.C. (2008). A tumor suppressor role for PP2A-
B56alpha through negative regulation of c-Myc and other key oncoproteins.
Cancer Metastasis Rev. 27, 147–158.
Baek, K.H., Zaslavsky, A., Lynch, R.C., Britt, C., Okada, Y., Siarey, R.J.,
Lensch, M.W., Park, I.H., Yoon, S.S., Minami, T., et al. (2009). Down’s syn-
drome suppression of tumour growth and the role of the calcineurin inhibitor
DSCR1. Nature 459, 1126–1130.Figure 7. Underexpression of ATF2-Dependent Transcripts in Human
(A) RCAN1 mRNA expression in normal liver compared to hepatocellular carcino
et al., 2010; Wurmbach et al., 2007).
(B) Expression of an ATF2-dependent gene signature in normal breast compared
(C) Underexpression of ATF2-dependent transcripts in several breast tumor type
2012).
(D) Underexpression of ATF2-dependent transcripts in breast tumors versus nor
TGCA (https://tcga-data.nci.nih.gov/tcga/).
(A–D) Analysis performed using the Oncomine database.
Cell ReBerger, A.J., Kluger, H.M., Li, N., Kielhorn, E., Halaban, R., Ronai, Z., and
Rimm, D.L. (2003). Subcellular localization of activating transcription factor 2
in melanoma specimens predicts patient survival. Cancer Res. 63, 8103–8107.
Bhoumik, A., Fichtman, B., Derossi, C., Breitwieser, W., Kluger, H.M., Davis,
S., Subtil, A., Meltzer, P., Krajewski, S., Jones, N., and Ronai, Z. (2008). Sup-
pressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc.
Natl. Acad. Sci. USA 105, 1674–1679.
Breitwieser, W., Lyons, S., Flenniken, A.M., Ashton, G., Bruder, G., Willington,
M., Lacaud, G., Kouskoff, V., and Jones, N. (2007). Feedback regulation of p38
activity via ATF2 is essential for survival of embryonic liver cells. Genes Dev.
21, 2069–2082.
Calvisi, D.F., Ladu, S., Conner, E.A., Seo, D., Hsieh, J.T., Factor, V.M., and
Thorgeirsson, S.S. (2011). Inactivation of Ras GTPase-activating proteins pro-
motes unrestrained activity of wild-type Ras in human liver cancer. J. Hepatol.
54, 311–319.
Cellurale, C., Weston, C.R., Reilly, J., Garlick, D.S., Jerry, D.J., Sluss, H.K., and
Davis, R.J. (2010). Role of JNK in a Trp53-dependent mouse model of breast
cancer. PLoS ONE 5, e12469.
Cellurale, C., Sabio, G., Kennedy, N.J., Das, M., Barlow, M., Sandy, P., Jacks,
T., and Davis, R.J. (2011). Requirement of c-Jun NH(2)-terminal kinase for Ras-
initiated tumor formation. Mol. Cell. Biol. 31, 1565–1576.
Cellurale, C., Girnius, N., Jiang, F., Cavanagh-Kyros, J., Lu, S., Garlick, D.S.,
Mercurio, A.M., and Davis, R.J. (2012). Role of JNK in mammary gland devel-
opment and breast cancer. Cancer Res. 72, 472–481.
Chen, X., Cheung, S.T., So, S., Fan, S.T., Barry, C., Higgins, J., Lai, K.M., Ji, J.,
Dudoit, S., Ng, I.O., et al. (2002). Gene expression patterns in human liver can-
cers. Mol. Biol. Cell 13, 1929–1939.
Chow, C.W., Rinco´n, M., Cavanagh, J., Dickens, M., and Davis, R.J. (1997).
Nuclear accumulation of NFAT4 opposed by the JNK signal transduction
pathway. Science 278, 1638–1641.
Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J.,
Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., et al.; METABRIC Group
(2012). The genomic and transcriptomic architecture of 2,000 breast tumours
reveals novel subgroups. Nature 486, 346–352.
Das, M., Garlick, D.S., Greiner, D.L., and Davis, R.J. (2011). The role of JNK in
the development of hepatocellular carcinoma. Genes Dev. 25, 634–645.
Dolado, I., Swat, A., Ajenjo, N., De Vita, G., Cuadrado, A., and Nebreda, A.R.
(2007). p38alpha MAP kinase as a sensor of reactive oxygen species in tumor-
igenesis. Cancer Cell 11, 191–205.
Eferl, R., Ricci, R., Kenner, L., Zenz, R., David, J.P., Rath, M., andWagner, E.F.
(2003). Liver tumor development. c-Jun antagonizes the proapoptotic activity
of p53. Cell 112, 181–192.
Esteva, F.J., Sahin, A.A., Smith, T.L., Yang, Y., Pusztai, L., Nahta, R., Buchholz,
T.A., Buzdar, A.U., Hortobagyi, G.N., and Bacus, S.S. (2004). Prognostic sig-
nificance of phosphorylated P38 mitogen-activated protein kinase and HER-2
expression in lymph node-positive breast carcinoma. Cancer 100, 499–506.
Galmiche, A., Chauffert, B., and Barbare, J.C. (2014). New biological perspec-
tives for the improvement of the efficacy of sorafenib in hepatocellular carci-
noma. Cancer Lett. 346, 159–162.
Greenman, C., Stephens, P., Smith, R., Dalgliesh, G.L., Hunter, C., Bignell, G.,
Davies, H., Teague, J., Butler, A., Stevens, C., et al. (2007). Patterns of somatic
mutation in human cancer genomes. Nature 446, 153–158.Tumors
ma. Graphs were produced from published data (Chen et al., 2002; Roessler
to mucinous breast carcinoma using published data (Curtis et al., 2012).
s versus normal breast. Heatmap produced using published data (Curtis et al.,
mal breast using data from two independent sources: Curtis et al. (2012) and
ports 9, 1361–1374, November 20, 2014 ª2014 The Authors 1373
Gupta, S., Campbell, D., De´rijard, B., and Davis, R.J. (1995). Transcription fac-
tor ATF2 regulation by the JNK signal transduction pathway. Science 267,
389–393.
Hu¨bner, A., Mulholland, D.J., Standen, C.L., Karasarides, M., Cavanagh-
Kyros, J., Barrett, T., Chi, H., Greiner, D.L., Tournier, C., Sawyers, C.L., et al.
(2012). JNK and PTEN cooperatively control the development of invasive
adenocarcinoma of the prostate. Proc. Natl. Acad. Sci. USA 109, 12046–
12051.
Hui, L., Bakiri, L., Mairhorfer, A., Schweifer, N., Haslinger, C., Kenner, L., Kom-
nenovic, V., Scheuch, H., Beug, H., and Wagner, E.F. (2007). p38alpha sup-
presses normal and cancer cell proliferation by antagonizing the JNK-c-Jun
pathway. Nat. Genet. 39, 741–749.
Hui, L., Zatloukal, K., Scheuch, H., Stepniak, E., and Wagner, E.F. (2008). Pro-
liferation of human HCC cells and chemically induced mouse liver cancers re-
quires JNK1-dependent p21 downregulation. J. Clin. Invest. 118, 3943–3953.
Jaworski, M., Buchmann, A., Bauer, P., Riess, O., and Schwarz, M. (2005). B-
raf and Ha-rasmutations in chemically inducedmouse liver tumors. Oncogene
24, 1290–1295.
Knippen, S., Lo¨ning, T., Mu¨ller, V., Schro¨der, C., Ja¨nicke, F., and Milde-Lan-
gosch, K. (2009). Expression and prognostic value of activating transcription
factor 2 (ATF2) and its phosphorylated form in mammary carcinomas. Anti-
cancer Res. 29, 183–189.
Labrakakis, C., Patt, S., Hartmann, J., and Kettenmann, H. (1998). Functional
GABA(A) receptors on human glioma cells. Eur. J. Neurosci. 10, 231–238.
Lee, S., Oh, T., Chung, H., Rha, S., Kim, C., Moon, Y., Hoehn, B.D., Jeong, D.,
Lee, S., Kim, N., et al. (2012). Identification of GABRA1 and LAMA2 as new
DNA methylation markers in colorectal cancer. Int. J. Oncol. 40, 889–898.
Lei, K., Nimnual, A., Zong, W.X., Kennedy, N.J., Flavell, R.A., Thompson, C.B.,
Bar-Sagi, D., and Davis, R.J. (2002). The Bax subfamily of Bcl2-related pro-
teins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal ki-
nase. Mol. Cell. Biol. 22, 4929–4942.
Ma, J., Arnold, H.K., Lilly, M.B., Sears, R.C., and Kraft, A.S. (2007). Negative
regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A.
Oncogene 26, 5145–5153.
Maekawa, T., Shinagawa, T., Sano, Y., Sakuma, T., Nomura, S., Nagasaki, K.,
Miki, Y., Saito-Ohara, F., Inazawa, J., Kohno, T., et al. (2007). Reduced levels of
ATF-2 predispose mice to mammary tumors. Mol. Cell. Biol. 27, 1730–1744.
Maekawa, T., Sano, Y., Shinagawa, T., Rahman, Z., Sakuma, T., Nomura, S.,
Licht, J.D., and Ishii, S. (2008). ATF-2 controls transcription of Maspin and
GADD45 alpha genes independently from p53 to suppress mammary tumors.
Oncogene 27, 1045–1054.
Mu¨ller, M.R., and Rao, A. (2010). NFAT, immunity and cancer: a transcription
factor comes of age. Nat. Rev. Immunol. 10, 645–656.
Newell, P., Toffanin, S., Villanueva, A., Chiang, D.Y., Minguez, B., Cabellos, L.,
Savic, R., Hoshida, Y., Lim, K.H., Melgar-Lesmes, P., et al. (2009). Ras
pathway activation in hepatocellular carcinoma and anti-tumoral effect of
combined sorafenib and rapamycin in vivo. J. Hepatol. 51, 725–733.
Raingeaud, J., Whitmarsh, A.J., Barrett, T., De´rijard, B., and Davis, R.J. (1996).
MKK3- andMKK6-regulated gene expression ismediated by the p38mitogen-
activated protein kinase signal transduction pathway.Mol. Cell. Biol. 16, 1247–
1255.
Rodgers, J.T., Vogel, R.O., and Puigserver, P. (2011). Clk2 and B56b mediate
insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on
Akt. Mol. Cell 41, 471–479.
Roessler, S., Jia, H.L., Budhu, A., Forgues, M., Ye, Q.H., Lee, J.S., Thorgeirs-
son, S.S., Sun, Z., Tang, Z.Y., Qin, L.X., and Wang, X.W. (2010). A unique
metastasis gene signature enables prediction of tumor relapse in early-stage
hepatocellular carcinoma patients. Cancer Res. 70, 10202–10212.1374 Cell Reports 9, 1361–1374, November 20, 2014 ª2014 The AutSakurai, T., Maeda, S., Chang, L., and Karin, M. (2006). Loss of hepatic NF-
kappa B activity enhances chemical hepatocarcinogenesis through sustained
c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. USA 103, 10544–
10551.
Salh, B., Marotta, A., Wagey, R., Sayed, M., and Pelech, S. (2002). Dysregula-
tion of phosphatidylinositol 3-kinase and downstream effectors in human
breast cancer. Int. J. Cancer 98, 148–154.
Shah, M., Bhoumik, A., Goel, V., Dewing, A., Breitwieser, W., Kluger, H., Kra-
jewski, S., Krajewska, M., Dehart, J., Lau, E., et al. (2010). A role for ATF2 in
regulating MITF and melanoma development. PLoS Genet. 6, e1001258.
Shibata, W., Maeda, S., Hikiba, Y., Yanai, A., Sakamoto, K., Nakagawa, H.,
Ogura, K., Karin, M., and Omata, M. (2008). c-Jun NH2-terminal kinase 1 is
a critical regulator for the development of gastric cancer in mice. Cancer
Res. 68, 5031–5039.
Stark, M.S., Woods, S.L., Gartside, M.G., Bonazzi, V.F., Dutton-Regester, K.,
Aoude, L.G., Chow, D., Sereduk, C., Niemi, N.M., Tang, N., et al. (2012).
Frequent somatic mutations inMAP3K5 andMAP3K9 in metastatic melanoma
identified by exome sequencing. Nat. Genet. 44, 165–169.
Steinmu¨ller, L., and Thiel, G. (2003). Regulation of gene transcription by a
constitutively active mutant of activating transcription factor 2 (ATF2). Biol.
Chem. 384, 667–672.
Stephens, P.J., Tarpey, P.S., Davies, H., Van Loo, P., Greenman, C., Wedge,
D.C., Nik-Zainal, S., Martin, S., Varela, I., Bignell, G.R., et al.; Oslo Breast Can-
cer Consortium (OSBREAC) (2012). The landscape of cancer genes andmuta-
tional processes in breast cancer. Nature 486, 400–404.
Su, L., Sampaio, A.V., Jones, K.B., Pacheco,M., Goytain, A., Lin, S., Poulin, N.,
Yi, L., Rossi, F.M., Kast, J., et al. (2012). Deconstruction of the SS18-SSX
fusion oncoprotein complex: insights into disease etiology and therapeutics.
Cancer Cell 21, 333–347.
Thomas, D.J., Rosenbloom, K.R., Clawson, H., Hinrichs, A.S., Trumbower, H.,
Raney, B.J., Karolchik, D., Barber, G.P., Harte, R.A., Hillman-Jackson, J.,
et al.; ENCODE Project Consortium (2007). The ENCODE Project at UC Santa
Cruz. Nucleic Acids Res. 35, D663–D667.
Ventura, J.J., Tenbaum, S., Perdiguero, E., Huth, M., Guerra, C., Barbacid, M.,
Pasparakis, M., and Nebreda, A.R. (2007). p38alpha MAP kinase is essential in
lung stem and progenitor cell proliferation and differentiation. Nat. Genet. 39,
750–758.
Wagner, E.F., and Nebreda, A.R. (2009). Signal integration by JNK and p38
MAPK pathways in cancer development. Nat. Rev. Cancer 9, 537–549.
Walczynski, J., Lyons, S., Jones, N., and Breitwieser, W. (2014). Sensitisation
of c-MYC-induced B-lymphoma cells to apoptosis by ATF2. Oncogene 33,
1027–1036.
Wang, S., Kang, X., Cao, S., Cheng, H., Wang, D., and Geng, J. (2012). Calci-
neurin/NFATc1 pathway contributes to cell proliferation in hepatocellular car-
cinoma. Dig. Dis. Sci. 57, 3184–3188.
Wurmbach, E., Chen, Y.B., Khitrov, G., Zhang, W., Roayaie, S., Schwartz, M.,
Fiel, I., Thung, S., Mazzaferro, V., Bruix, J., et al. (2007). Genome-wide molec-
ular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepa-
tology 45, 938–947.
Yang, Y.M., Bost, F., Charbono, W., Dean, N., McKay, R., Rhim, J.S., Depatie,
C., and Mercola, D. (2003). C-Jun NH(2)-terminal kinase mediates proliferation
and tumor growth of human prostate carcinoma. Clin. Cancer Res. 9, 391–401.
Zender, L., Spector, M.S., Xue, W., Flemming, P., Cordon-Cardo, C., Silke, J.,
Fan, S.T., Luk, J.M., Wigler, M., Hannon, G.J., et al. (2006). Identification and
validation of oncogenes in liver cancer using an integrative oncogenomic
approach. Cell 125, 1253–1267.hors
